Despite Early Promise GLP-1 Disappoints in Parkinson’s
Treatment with the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide had no disease-modifying effects on movement, symptom severity or brain imaging in patients with Parkinson’s disease (PD) enrolled in a phase 3 trial. “The results of this trial have been eagerly anticipated, and the negative results will be a major disappointment to patients affected by … Read more